Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Enfuvirtide Acetate is a synthetic peptide fusion inhibitor used in HIV-1 treatment. Produced via solid-phase synthesis, its molecular formula is C<sub>76</sub>H<sub>114</sub>N<sub>20</sub>O<sub>24</sub>·C<sub>2</strong><strong>H<sub>4</sub>O<sub>2</sub></strong> with CAS 95863-10-6.</p>
<h3>Application</h3>
<ul>
<li>HIV-1 therapy: Combined with other antiretrovirals for multidrug-resistant cases.</li>
<li>Clinical trials: Investigated for pre-exposure prophylaxis (PrEP) efficacy.</li>
<li>Pharmaceutical manufacturing: Sourced as API for injectable formulation production.</li>
</ul>
<h3>Precautions</h3>
<p>Restricted to parenteral use only; requires strict aseptic handling. Store at -20°C protected from light. Monitor for injection site reactions and hypersensitivity during clinical administration.</p>